If you have been reading about dual agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-06. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Estradiol has been studied and used by intranasal administration. It was available as a cyclodextrin-containing nasal spray under the brand name Aerodiol in some countries, although this specific product was discontinued in 2007. The product was administered once per day as one 150-μg spray in each nostril (300 μg/day total). Intranasal estradiol has pharmacokinetics similar to those of sublingual and intravenous administration of estradiol, including a sharp peak and then rapid decline in estradiol levels. Despite the relatively short duration of intranasal estradiol, it has similar effectiveness to other, longer-lasting routes of administration in terms of relief of menopausal symptoms like hot flashes.
On the basis of Gennaro's histological studies and the present amino acid and Cu and Fe analyses, I conclude that, to the extent the preserved O. giganteus tissue is representative of the carcass washed ashore at St. Augustine, Florida, in November 1896, it was essentially a huge mass of collagenous protein. Certainly, the tissue was not blubber. I interpret these results as consistent with, and supportive of, Webb and Verrill's identification of the carcass as that of a gigantic cephalopod, probably an octopus, not referable to any known species.
Such was the day for our regimentDread the revenge we will take.Dearly we paid for the blunder –A drawing-room General's mistake.Why weren't we told of the trenches?Why weren't we told of the wire? Why were we marched up in column,May Tommy Atkins enquire ... The nadir of Black Week was the Second Battle of Colenso on 15 December, where 21,000 British troops, commanded by Buller, attempted to cross the Tugela River to relieve Ladysmith, where 8,000 Transvaal Boers under the command of Louis Botha were waiting. Through a combination of artillery and accurate rifle fire and better use of the ground, the Boers repelled British attempts to cross the river. After his first attacks failed, Buller broke off the battle and ordered a retreat, abandoning many wounded men, several isolated units and ten field guns to be captured by Botha's men. Buller's forces lost 145 men killed and 1,200 missing or wounded and the Boers suffered only 40 casualties, including 8 killed.
=== Eyes === Cases of severe conjunctivitis were reported after technicians looked into powered waveguides. Microwave-induced cataracts have been reported. Experiments on rabbits and dogs, mostly in the UHF range of frequencies, shown that the ocular effects are confined to eyelids and conjunctiva (as e.g. anterior segment keratitis or iritis). Cataracts were observed at several workers exposed to radiofrequency radiation, but in some of the cases the cause was unrelated to the RF exposure and in the other cases the evidence was incomplete or inconclusive. Some sources however mention incidence of microwave-related injuries of ocular lens and retina and the possibility of thermal effects to cause cataracts or focal tissue burns (including keratitis). For the near field 2.45 GHz frequency, the minimum power density to cause cataracts in rabbits was found to be 150 mW/cm2 for 100 minutes; a retrolental temperature of 41 °C was necessary to be achieved. When the eye temperature was kept low by external cooling, cataracts were not produced by higher field intensities; that supports the hypothesis of a thermal mechanism being involved.
Sources: en.wikipedia.org
Other impacts on exposure in utero PFOA exposure on thyroid function has also been a topic of concern, and has found to negatively impact thyroid stimulating hormone even at low levels when exposed during fetal development. PFOA is also shown to have obesogenic effects, and an experimental study found a positive correlation to low-dose prenatal exposure of PFOA and prevalence of overweight and high waist circumference in females at age 20. A correlation between in utero PFOA exposure and mental performance has yet to be established, as many studies have resulted in insignificant results. For example, a study conducted near Parkersburg, West Virginia did not find a significant association between in utero PFOA exposure and performance of math skills or reading performance in children ages 6 to 12 living in the PFOA-contaminated water district. Based on a cohort study conducted in the Mid-Ohio Valley, no clear association was found between prenatal exposure to PFOA and birth defects, although a possible association with brain defects was observed and requires further research and assessment. Extrapolated epidemiological data suggests a slight association between PFOA exposure and low birth weight. This was consistent based on blood levels of PFOA metabolites regardless of the geographic residence of subjects. Generally, the findings among human fetuses exposed to the chemical were considerably less drastic than what was seen in mice studies. Because of this, studies linking exposure to low birth weight can be considered inconclusive.
During the 2025 legislative session, Moore introduced the Excellence in Maryland Public Schools Act, which proposed temporary pauses on plans under the Blueprint to gradually give teachers more "collaborative time" to work on professional development and planning outside of the classroom, reduce funding for programs to support students learning English, and freeze funding for community schools for two years. These proposed changes would cut nearly one-fifth of new funding provided under the Blueprint reforms and have the most impact on students living in poverty and immigrant students. Moore's proposed Blueprint reforms were largely rejected by lawmakers, who amended Moore's bill to reinstate funding for community schools and students learning English, but implemented a three-year delay on collaborative time implementation plans. Moore signed the Excellence in Maryland Public Schools Act into law in May 2025.
These findings extend the use of MPPT into dermatology and positive effects have been observed in hidradenitis suppurativa. The MPPT technology has been approved in the EU as a "treatment for wounds" and is currently the only wound product with this approval. Other medical devices for wounds are approved to have a certain effect on the wound, e.g. add moisture or remove wound exudate, but they are not recognised as treatments.
Sources: en.wikipedia.org
== Chemistry of experiment == In 1957 Miller published research describing the chemical processes occurring inside his experiment. Hydrogen cyanide (HCN) and aldehydes (e.g., formaldehyde) were demonstrated to form as intermediates early on in the experiment due to the electric discharge. This agrees with current understanding of atmospheric chemistry, as HCN can generally be produced from reactive radical species in the atmosphere that arise when CH4 and nitrogen break apart under ultraviolet (UV) light. Similarly, aldehydes can be generated in the atmosphere from radicals resulting from CH4 and H2O decomposition and other intermediates like methanol. Several energy sources in planetary atmospheres can induce these dissociation reactions and subsequent hydrogen cyanide or aldehyde formation, including lightning, ultraviolet light, and galactic cosmic rays. For example, here is a set photochemical reactions of species in the Miller–Urey atmosphere that can result in formaldehyde:
== Alternative medicine == Triiodothyronine has been used to treat Wilson's syndrome, an alternative medical diagnosis not recognized as a medical condition by mainstream medicine. This diagnosis involves various non-specific symptoms that are attributed to the thyroid, despite normal thyroid function tests. The American Thyroid Association has raised concern that the prescribed treatment with triiodothyronine is potentially harmful.
Broad proteomic and transcriptomic profiling has led to innumerable advances in the biomedical space, but the characterization of RNA and protein expression is limited in its ability to inform on the functional characteristics of proteins. Given that transcript and protein expression information leave gaps in knowledge surrounding the effects of post-translational modifications and protein-protein interactions on enzyme activity, and that enzyme activity varies across cell types, disease states, and physiological conditions, specialized tools are required to profile enzyme activity across contexts. Additionally, many identified enzymes have not been sufficiently characterized to yield actionable mechanisms on which to base functional assays. Without a basis for a functional biochemical readout, chemical tools are required to detect drug-protein interactions.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.